XML 62 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jan. 31, 2018
Oct. 31, 2017
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Summary Of Significant Accounting Policies [Line Items]          
Credit losses on marketable securities     $ 0 $ 0  
Impairment loss on right-of-use assets     238,000 1,158,000  
Deferred revenue     $ 132,300,000    
Increase in the forecast of total expected costs     7.00%    
Reduction in revenue due to increase in budget during the year     $ 6,700,000    
Defined contribution plan, maximum annual contributions per employee, percent     100.00%    
Defined matching contribution plan     $ 700,000 0 $ 0
AbbVie Biotechnology Limited          
Summary Of Significant Accounting Policies [Line Items]          
Upfront payments   $ 205,000,000      
Upfront payment received $ 200,000,000 5,000,000      
Exclusive option rights exercised for each program   250,000,000      
Cash payment received, non-refundable $ 200,000,000 5,000,000      
AbbVie Biotechnology Limited | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Summary Of Significant Accounting Policies [Line Items]          
Collaboration revenue     21,100,000 $ 21,200,000 $ 27,500,000
Innovent          
Summary Of Significant Accounting Policies [Line Items]          
Collaboration revenue     0    
Development milestone     11,500,000    
Sales milestone     $ 112,500,000    
Minimum          
Summary Of Significant Accounting Policies [Line Items]          
Property, plant, and equipment useful life     3 years    
Maximum          
Summary Of Significant Accounting Policies [Line Items]          
Property, plant, and equipment useful life     5 years    
Maximum | AbbVie Biotechnology Limited          
Summary Of Significant Accounting Policies [Line Items]          
Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval   $ 242,800,000